- Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
- Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors
- Orchestra BioMed Demonstrates Strength of Cardiovascular Pipeline with Virtue® SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting
- Orchestra BioMed to Participate in Upcoming Investor Conferences
- Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients
- Orchestra BioMed Presents New Data Showing Sustained Clinically Meaningful Reduction in 24-Hour Ambulatory Systolic Blood Pressure in Hypertensive Pacemaker Patients Treated with AVIM Therapy for Over 3 Years
- Orchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business Update
- Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients
- Orchestra BioMed Reports Second Quarter 2023 Financial Results and Provides Business Update
- Orchestra BioMed™ Granted FDA Approval of IDE for U.S. Pivotal Study of Virtue® Sirolimus AngioInfusion Balloon™ in Patients with Coronary In-Stent Restenosis
More ▼
Key statistics
As of last trade Orchestra Biomed Holdings Inc (OBIO:NMQ) traded at 4.47, 5.05% above its 52-week low of 4.26, set on Oct 26, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.50 |
---|---|
High | 4.51 |
Low | 4.45 |
Bid | 4.45 |
Offer | 4.70 |
Previous close | 4.50 |
Average volume | 27.18k |
---|---|
Shares outstanding | 35.78m |
Free float | 21.83m |
P/E (TTM) | -- |
Market cap | 161.00m USD |
EPS (TTM) | -1.49 USD |
Data delayed at least 15 minutes, as of Apr 23 2024 17:19 BST.
More ▼